Top Markets
Coin of the day
Yumanity Therapeutics, Inc. Yumanity Therapeutics, Inc.

Yumanity Therapeutics, Inc.

YMTX
Rangering i aksjer #28846
Yumanity Therapeutics Inc. operates as a clinical-stage biopharmaceutical... Yumanity Therapeutics Inc. operates as a clinical-stage biopharmaceutical company. Its primary focus lies in the investigation and development of therapeutic solutions for neurodegenerative conditions, particularly those driven by protein misfolding. The firm aims to discover disease-modifying treatments for a range of neurodegenerative disorders, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis (ALS), and frontotemporal lobar degeneration. Central to its pipeline is YTX-7739, an innovative small molecule presently in Phase I clinical trials for Parkinson's disease and associated α-synuclein disorders. Additionally, YTX-9184 is undergoing preclinical studies with the goal of treating diverse neurological conditions. The company maintains a license and research collaboration agreement with Merck Sharp & Dohme Corp. Founded in 2014, Yumanity Therapeutics Inc. is headquartered in Boston, Massachusetts.
Aksjekurs
$1.89
Sist synkronisert: 2022-12-16
Markedsverdi
$24.38M
Endring (1 dag)
8.62%
Endring (1 år)
0.00%
Land
US
Handel Yumanity Therapeutics, Inc. (YMTX)

Kategori

EPS for Yumanity Therapeutics, Inc. (YMTX)
EPS per 2026 TTM: 0
Ifølge de siste økonomiske rapportene og aksjekursen til Yumanity Therapeutics, Inc. er selskapets nåværende EPS (TTM) 0. Ved slutten av 2026 hadde selskapet en EPS på 0, lik EPS-en i 2026 som var 0.
EPS-historikk for Yumanity Therapeutics, Inc. fra 2026 til 2026
EPS ved slutten av hvert år
År EPS Endre
Ikke nok data for de angitte datoene.
EPS for lignende selskaper eller konkurrenter
Selskap EPS EPS-forskjell Land
$17.32 -
US
$-7.98 -
US
$27.74 -
NL
$2.98 -
AU
- -
CH